Reversible bull's-eye maculopathy associated with intravitreal fomivirsen therapy for cytomegalovirus retinitis.

Abstract

PURPOSE:

To report two cases in which a bull's eye maculopathy developed after intravitreal injection of fomivirsen.

METHODS:

Case reports.

RESULTS:

A 50-year-old man with acquired immunodeficiency syndrome (AIDS) and refractory cytomegalovirus retinitis developed bull's-eye pigmentary changes in the macula of the right eye after initiating therapy with fomivirsen (Vitravene; CIBA Vision, Atlanta, Georgia) intravitreal injections. These pigmentary changes resolved upon cessation of treatment. A 36-year-old man with AIDS and refractory bilateral cytomegalovirus retinitis developed bull's-eye pigmentary changes in both eyes during bilateral intravitreal treatment with fomivirsen. Vision was not affected. These changes resolved after treatment with fomivirsen was stopped.

CONCLUSION:

Fomivirsen, a new medication for the treatment of refractory cytomegalovirus retinitis, may cause a bull's-eye maculopathy in some patients. The bull's-eye maculopathy is reversible and does not appear to affect vision.

• Authors: T W Stone, G J Jaffe
• Journal: American journal of ophthalmology (Am J Ophthalmol) Vol. 130 Issue 2 Pg. 242-3 (Aug 2000) ISSN: 0002-9394 [Print] United States
• PMID: 11004306 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Antiviral Agents
• Thionucleotides
• fomivirsen

Topics

• AIDS-Related Opportunistic Infections (drug therapy)
• Adult
• Antiviral Agents (adverse effects, therapeutic use)
• Cytomegalovirus Retinitis (drug therapy)
• Humans
• Injections
• Macula Lutea (drug effects, physiopathology)
• Male
• Middle Aged
• Retinal Diseases (chemically induced, physiopathology)
• Thionucleotides (adverse effects, therapeutic use)
• Visual Acuity
• Vitreous Body